Nanoform announced that it has established Nanoform USA Inc., a wholly owned subsidiary in the U.S. This is a natural progression for the company as it continues to increase the impact of its award-winning nanonization technology and expand its major pharma client base in the US. The establishment of Nanoform USA Inc. follows the recent appointment of Sally Langa as Head of U.S. Sales. Sally brings 30 years of valuable commercial experience in Pharma, having held senior positions at Catalent Pharma, Patheon and Halo Pharmaceutical.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.986 EUR | -0.70% | -5.88% | +25.30% |
05-30 | Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-30 | Transcript : Nanoform Finland Oyj, Q1 2024 Earnings Call, May 30, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.30% | 186M | |
+52.14% | 55.7B | |
+41.08% | 39.91B | |
-6.08% | 39.57B | |
-5.56% | 28.16B | |
+15.38% | 26.3B | |
-19.66% | 18.94B | |
+30.89% | 12.17B | |
+26.61% | 12.12B | |
+1.31% | 12.12B |
- Stock Market
- Equities
- NANOFH Stock
- News Nanoform Finland Oyj
- Nanoform Establishes U.S. Subsidiary; Appoints Sally Langa as Head of U.S. Sales